Health Economics›Gastrointestinal stromal tumor›Metastatic or unresectable disease fourth-line

Metastatic or unresectable disease fourth-line

Gastrointestinal stromal tumor · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ripretinib monotherapy Variant #01 Partial	—	—	28d	6.3 mo	—	7	—	1
Avapritinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Pimitespib monotherapy Variant #01 Partial	—	—	21d	—	13.8 mo	—	—	1

3 of 3 regimens shown